<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="97230"><DrugName>AMV-564</DrugName><DrugSynonyms><Name><Value>anti-CD3/anti-CD33 bispecific T-cell engager (cancer), Amphivena Therapeutics/Janssen</Value></Name><Name><Value>AMV-564</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1107363">Amphivena Therapeutics Inc</CompanyOriginator><CompaniesPrimary><Company id="26997">Janssen Biotech Inc</Company><Company id="1107363">Amphivena Therapeutics Inc</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1107363" type="Company"><TargetEntity id="5040202118" type="organizationId">Amphivena Therapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="26997" type="Company"><TargetEntity id="4295909367" type="organizationId">Janssen Biotech Inc</TargetEntity></SourceEntity><SourceEntity id="1272" type="ciIndication"><TargetEntity id="D46" type="ICD10"/><TargetEntity id="10028533" type="MEDDRA"/><TargetEntity id="D011289" type="MeSH"/><TargetEntity id="-376765165" type="omicsDisease"/><TargetEntity id="711" type="siCondition"/></SourceEntity><SourceEntity id="1731" type="ciIndication"><TargetEntity id="D015470" type="MeSH"/><TargetEntity id="519" type="ORPHANET"/><TargetEntity id="-1550871001" type="omicsDisease"/><TargetEntity id="686" type="siCondition"/></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="55684" type="Action"><TargetEntity id="3131" type="Mechanism">Anti-Thomsen-Friedenreich Antigen (CD176)</TargetEntity><TargetEntity id="3993" type="Mechanism">Anti-Stage-Specific Embryonic Antigen (SSEA)-5 (Anti-H Type-1 Antigen)</TargetEntity><TargetEntity id="4126" type="Mechanism">Anti-Globo H</TargetEntity><TargetEntity id="3601" type="Mechanism">Anti-Tn Antigen</TargetEntity><TargetEntity id="3294" type="Mechanism">Drugs Targeting Cancer Associated Antigens</TargetEntity></SourceEntity><SourceEntity id="5119" type="Action"><TargetEntity id="6705" type="Mechanism">Drugs Targeting Myeloid Cell Surface Antigen CD33</TargetEntity></SourceEntity><SourceEntity id="PTGT-09554" type="ciTarget"><TargetEntity id="10390460159453" type="siTarget">Myeloid cell surface antigen CD33</TargetEntity><TargetEntity id="-1054018485" type="omicsTarget"/></SourceEntity><SourceEntity id="PTGT-16897" type="ciTarget"><TargetEntity id="82621" type="siTarget">CD3 Complex (T Cell Receptor Complex)</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C1">Phase 1 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1272">Myelodysplastic syndrome</Indication><Indication id="1731">Acute myelogenous leukemia</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsPrimary><Action id="5023">CD3 modulator</Action><Action id="5119">CD33 modulator</Action></ActionsPrimary><ActionsSecondary><Action id="7761">T-lymphocyte stimulator</Action><Action id="55684">Anticancer antibody</Action><Action id="393">Immunostimulant</Action></ActionsSecondary><Technologies><Technology id="1263">Immuno-oncology</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="740">Infusion</Technology><Technology id="538">Humanized antibody</Technology><Technology id="267">Multivalent antibody</Technology></Technologies><EphmraCodes><Ephmra><Code>L3</Code><Name>IMMUNOSTIMULATING AGENTS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-06-28T11:38:10.000Z</LastModificationDate><ChangeDateLast>2019-01-10T00:00:00.000Z</ChangeDateLast><AddedDate>2015-05-13T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1107363" linkType="Company"&gt;Amphivena Therapeutics&lt;/ulink&gt;  and &lt;ulink linkID="26997" linkType="Company"&gt;Janssen Biotech&lt;/ulink&gt; are developing AMV-564, a humanized bispecific tetravalent CD33/CD3 antibody based on &lt;ulink linkID="30783" linkType="Company"&gt;Affimed&lt;/ulink&gt; technology, for the potential iv treatment  of  cancer including acute myeloid leukemia (AML)  [&lt;ulink linkID="1663264" linkType="Reference"&gt;1663264&lt;/ulink&gt;], [&lt;ulink linkID="1775036" linkType="Reference"&gt;1775036&lt;/ulink&gt;], [&lt;ulink linkID="1926944" linkType="Reference"&gt;1926944&lt;/ulink&gt;], [&lt;ulink linkID="1949868" linkType="Reference"&gt;1949868&lt;/ulink&gt;].  Amphivena is also investigating the antibody for the potential treatment of myelodysplastic syndrome (MDS)  [&lt;ulink linkID="1960997" linkType="Reference"&gt;1960997&lt;/ulink&gt;]. In March 2017, a phase I study began in patients with relapsed or refractory AML  [&lt;ulink linkID="1926944" linkType="Reference"&gt;1926944&lt;/ulink&gt;]; in June 2018, data were presented [&lt;ulink linkID="2045500" linkType="Reference"&gt;2045500&lt;/ulink&gt;], [&lt;ulink linkID="2045895" linkType="Reference"&gt;2045895&lt;/ulink&gt;]. In September 2017, a phase I study in patients with MDS  was to begin  in early 2018 [&lt;ulink linkID="1960997" linkType="Reference"&gt;1960997&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In November 2017, Amphivena Therapeutics received Orphan Drug designation from the US FDA for AMV-564 for the treatment of AML [&lt;ulink linkID="1986473" linkType="Reference"&gt;1986473&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In August 2016, the US FDA  accepted an IND application for  AMV-564. The company was planning to initiate a dose-escalation, phase I trial in patients with  acute myeloid leukemia (AML) to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating AMV-564 that year   [&lt;ulink linkID="1787242" linkType="Reference"&gt;1787242&lt;/ulink&gt;], [&lt;ulink linkID="1912977" linkType="Reference"&gt;1912977&lt;/ulink&gt;]. In March 2017, an open-label, unmasked, single-group assigned, dose-escalation, first-in-human, phase I study  (&lt;ulink linkID="297552" linkType="Protocol"&gt;NCT03144245&lt;/ulink&gt;; AMV564-101) began in the US to examine qd AMV-564, in patients (expected n = 50) with relapsed or refractory AML. In May 2017, the study was to complete in February 2020 [&lt;ulink linkID="1926944" linkType="Reference"&gt;1926944&lt;/ulink&gt;]. In May 2018, recruitment was ongoing [&lt;ulink linkID="2034316" linkType="Reference"&gt;2034316&lt;/ulink&gt;]. In June 2018, data were presented at the 23rd EHA Annual Congress in Stockholm, Sweden. AMV-564 demonstrated a gradual accumulation to steady state, a terminal half-life of approximately 2 days and reduced renal clearance compared with monovalent, bispecific T-cell engagers. Treatment-emergent adverse events were mild with no grade 3 or above adverse events observed. In addition, cytokine release syndrome did not occur in the &amp;lt;/= 15-microg groups. In the 50-microg dose group, cytokine release syndrome of grade 2 severity that was described as manageable was reported in 1 patient. The 30-day mortality was 0%, with repeated treatment cycles well tolerated. Efficacy analysis revealed bone marrow blast reductions of between 13 to 38% in 10 out of 15 evaluable patients. Extramedullary improvement of reduction in spleen size was also observed [&lt;ulink linkID="2045500" linkType="Reference"&gt;2045500&lt;/ulink&gt;], [&lt;ulink linkID="2045895" linkType="Reference"&gt;2045895&lt;/ulink&gt;], [&lt;ulink linkID="2044969" linkType="Reference"&gt;2044969&lt;/ulink&gt;]. In December 2018, further results were presented at 60th ASH Annual Meeting and Exposition in San Diego, CA. DLTs were not observed through dose levels 150 microg. With continuous iv infusion, drug concentration increased gradually to steady-state, with concentrations decreasing with a multi-phasic profile. Blast reductions were observed in 16 out of 26 poor prognosis AML patients, with partial response and complete remission with incomplete hematologic recovery at 100 microg [&lt;ulink linkID="2098761" linkType="Reference"&gt;2098761&lt;/ulink&gt;], [&lt;ulink linkID="2101017" linkType="Reference"&gt;2101017&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In December 2018, in vivo data were presented at the 60th ASH Annual Meeting and Exposition in San Diego, CA. In an aggressive model of AML,  AMV-564 (5 microg/day x 4 days, iv) improved survival by approximately 10 days when 2 x 10(6) T-cells (iv) were administered on day 7 along with either 1 or 2 cycles of AMV-564 started on days 7 and 22. With T-cells at 8 x 10(6) and a single cycle of AMV-564 (5 microg/day x 5 days) initiated 3 days after tumor cells injection, best survival and a sustained and profound control of the very aggressive MOLM-13(CG) cell line was observed [&lt;ulink linkID="2098877" linkType="Reference"&gt;2098877&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2018, in vivo data were presented at the 109th AACR Annual Meeting in Chicago, IL. In cynomolgus monkeys, the continuous iv administration of AMV-564 at 10, 20 or 30 mcg/kg (low, intermediate and high doses, respectively) for 14 days showed no severe effects and was well tolerated; and the highest non-toxic dose was considered as 30 mcg/kg/day [&lt;ulink linkID="2021994" linkType="Reference"&gt;2021994&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2017, in vitro data were presented at the 59th ASH Annual Meeting and Exposition in Atlanta, GA. In primary bone marrow mononuclear cells (BMMNC) from MDS patients, AMV-564 treatment eliminated CD33Hi myeloid-derived suppressor cells in a dose-dependent manner (p &amp;lt;/= 0.001 versus control) and activated CD4+ and CD8+ T-cells. AMV-564 depletion of MDSC induced proportionate T cell activation, improved colony-forming capacity (p = 0.018) and decreased DNA damage in CD34+ HSPC. AMV-564 depletion of MDSC enhanced CD4 and CD8 T-cell response to programmed cell death-1 protein blockade [&lt;ulink linkID="1988960" linkType="Reference"&gt;1988960&lt;/ulink&gt;], [&lt;ulink linkID="1990171" linkType="Reference"&gt;1990171&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By September 2017, the antibody had demonstrated therapeutic window in cynomologus monkeys, with rapid, sustained elimination of CD33-expressing cells  [&lt;ulink linkID="1960997" linkType="Reference"&gt;1960997&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2015, preclinical data were presented at the 51st ASCO meeting in Chicago, IL. 									AMV-564 had CD3 (human T-cells) and CD33 (HL-60 cells) Kd values of 5.1 and 0.3 nM, respectively and also showed activity against CD25 induction, CD69 induction and T-cell proliferation in PBMC with EC50 values of 1, 2 and 3 pM, respectively, with 86 and 81.3% cytotoxicity against HL-60 and KG-1a cells, respectively [&lt;ulink linkID="1663613" linkType="Reference"&gt;1663613&lt;/ulink&gt;], [&lt;ulink linkID="1664749" linkType="Reference"&gt;1664749&lt;/ulink&gt;], [&lt;ulink linkID="1665342" linkType="Reference"&gt;1665342&lt;/ulink&gt;]. Further preclinical data were also presented at the same conference showing that in a prophylactic and in an established HL-60 xenograft NOD/scid mouse models, AMV-564 exhibited a dose-dependent tumor growth delay and substantially inhibited tumor growth, respectively [&lt;ulink linkID="1663617" linkType="Reference"&gt;1663617&lt;/ulink&gt;]. Further preclinical data were also presented at the same conference showing that in NSG mice bearing patient T cells, treatment with AMV-564 did not result in a long-term increase in T cell numbers and facilitated clearance of human AML blasts. AMV-564 specifically lysed human CD33+ target cell lines, but not human cells lacking the antigen [&lt;ulink linkID="1670324" linkType="Reference"&gt;1670324&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2015, the company was   completing IND-enabling studies to advance the program into clinical development [&lt;ulink linkID="1663264" linkType="Reference"&gt;1663264&lt;/ulink&gt;],   [&lt;ulink linkID="1663613" linkType="Reference"&gt;1663613&lt;/ulink&gt;],  [&lt;ulink linkID="1664749" linkType="Reference"&gt;1664749&lt;/ulink&gt;], [&lt;ulink linkID="1665342" linkType="Reference"&gt;1665342&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2015, the company was planning to present the positive preclinical data at 2015, ASCO Annual Meeting, Chicago, IL [&lt;ulink linkID="1663264" linkType="Reference"&gt;1663264&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2015, preclinical data were reported. Data demonstrated that the antibodies showed potent and selective killing of CD33 positive AML cells in vitro and impressive activity in AML animal models in vivo [&lt;ulink linkID="1663264" linkType="Reference"&gt;1663264&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate>2017-03-20T00:00:00.000Z</StatusDate><Source id="1926944" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1107363">Amphivena Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2017-03-20T00:00:00.000Z</StatusDate><Source id="1926944" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1107363">Amphivena Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate>2017-09-11T00:00:00.000Z</StatusDate><Source id="1960997" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1107363">Amphivena Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2015-05-26T00:00:00.000Z</StatusDate><Source id="1663264" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2015-05-26T00:00:00.000Z</StatusDate><Source id="1663264" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1107363">Amphivena Therapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of Acute Myeloid Leukemia </AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2017-11-29T00:00:00.000Z</MileStoneDate><Source id="1986473" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-09554"><Name>CD33</Name><SwissprotNumbers><Swissprot>P20138</Swissprot><Swissprot>Q63994</Swissprot></SwissprotNumbers></Target><Target id="PTGT-16897"><Name>CD3</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="17332">Johnson &amp; Johnson</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="30783">Affimed NV</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="146688" title="Amphivena and Janssen Biotech to develop bispecific TandAb for hematologic tumors"/></Deals><PatentFamilies><PatentFamily id="3471662" number="WO-2016196230" title="Methods of using bispecific CD33 and CD3 binding proteins"/><PatentFamily id="4013800" number="WO-2016004108" title="Bispecific cd33 and cd3 binding proteins"/><PatentFamily id="4475562" number="WO-2019075413" title="Dosing regimen for CD3 binding proteins"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tocagen Inc" id="1051749"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Harpoon Therapeutics Inc" id="1138978"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Affimed NV" id="30783"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>